GDC 5780
Alternative Names: GDC-5780Latest Information Update: 28 Apr 2025
At a glance
- Originator Genentech
- Class Antibacterials; Small molecules; Urinary anti-infective agents
- Mechanism of Action Type I signal peptidase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Enterobacteriaceae infections
- No development reported Urinary tract infections
Most Recent Events
- 28 Apr 2025 No recent reports of development identified for phase-I development in Urinary-tract-infections(In volunteers) in USA (IV, Infusion)
- 27 Apr 2024 Pharmacodynamics data from a preclinical studies in Enterobacteriaceae infections presented at the 34th Congress of the European Society of Clinical Microbiology and Infectious (ESCMID-2024)
- 27 Apr 2024 Preclinical trials in Enterobacteriaceae-infections in USA (unspecified route)